Multicomponent reactions (MCRs) are one-pot reactions employing more than two starting
materials, for example, 3, 4,..., 7, where most of the atoms of the starting materials are …

The tumour suppressor p53 is the most frequently mutated gene in human cancer, with more
than half of all human tumours carrying mutations in this particular gene. Intense efforts to …

Design of small-molecule inhibitors (MDM2 inhibitors) to block the MDM2–p53 protein–
protein interaction has been pursued as a new cancer therapeutic strategy. In recent years …

Since Hedin's characterization of trypsin and antitrypsin in 1906,(1) arguably the first
account of a regulatory protein–protein interaction (PPI), contemporary understanding of …

Multicomponent reactions are flexible reactions for the rapid generation of complex
molecules with often biologically relevant scaffold structures. Combined with the ease of …

Multicomponent reactions (MCRs), which are located between one‐and two‐component
and polymerization reactions, provide a number of valuable conceptual and synthetic …

We previously reported the discovery of a class of spirooxindoles as potent and selective
small-molecule inhibitors of the MDM2–p53 interaction (MDM2 inhibitors). We report herein …

Peptide modifications can unlock a variety of compounds with structural diversity and
abundant biological activity. In nature, peptide modifications, such as functionalisation at the …

Benzodiazepines (BZDs), a diverse class of benzofused seven-membered N-heterocycles,
display essential pharmacological properties and play vital roles in some biochemical …

Targeting protein–protein interactions (PPIs) has emerged as a viable approach in modern
drug discovery. However, the identification of small molecules enabling us to effectively …